Studies have shown that active fund managers routinely underperform the S&P500 index*​

Neumora Therapeutics, Inc. (NASDAQ: NMRA)

NMRA Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
BUY
Analyst Forecast (1yr):
367%

NMRA Stock Analysis

NMRA PE Ratio:

NMRA PEG Ratio: Not Available

NMRA Forward EPS Growth (12 month): 0.00%

NMRA PS Ratio:

NMRA PSG Ratio: Not Available

NMRA Forward Revenue Growth (12 month): 0.00%

NMRA Articles

No data was found